As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.
11 Analysts have issued a Dynavax Technologies Corporation forecast:
11 Analysts have issued a Dynavax Technologies Corporation forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 331 331 |
27%
27%
|
|
| Gross Profit | 275 275 |
27%
27%
|
|
| EBITDA | 13 13 |
4,097%
4,097%
|
|
| EBIT (Operating Income) EBIT | 10 10 |
240%
240%
|
|
| Net Profit | -43 -43 |
312%
312%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
| Head office | United States |
| CEO | Ryan Spencer |
| Employees | 405 |
| Founded | 1996 |
| Website | www.dynavax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


